ASP Isotopes invests $5 million in radiotherapeutic startup IsoBio

ASP Isotopes Inc. (NASDAQ: ASPI) completed a $5 million Series Seed funding round for IsoBio Inc., a radiotherapeutic development company focused on antibody-isotope conjugates for cancer treatment.

IsoBio develops treatments using monoclonal antibodies combined with radioactive isotopes including Lutetium-177, Actinium-225, and Terbium-161. The company plans to target both validated and novel tumor antigens using proprietary linker and conjugation technology.

The strategic partnership provides IsoBio access to ASP Isotopes' isotope production capabilities and its nuclear medicine subsidiary PET Labs for potential future manufacturing. ASP Isotopes specializes in isotope enrichment using its Aerodynamic Separation Process technology.

IsoBio was co-founded by Bruce Turner, M.D., Ph.D., who previously co-led the merger creating Immunome Inc. (NASDAQ: IMNM) and founded Xanadu Bio. Turner also served as an executive at Roche Pharmaceuticals. The company will establish offices in Seattle, Washington and Gladwyne, Pennsylvania.

"My entire career has been spent caring for and treating cancer patients. Now with the help of ASPI and PET Labs we will be able to quickly create novel radioisotopes using established antibodies that have been validated by regulatory authorities," Turner stated according to the press release.

The companies plan to host an investor webcast on July 30, 2025, at 10 a.m. EST to discuss the collaboration.

ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, and focuses on producing isotopes for healthcare, technology, and nuclear energy applications.

You May Also Be Interested In